Definitive Healthcare CLO granted 481,505 RSUs

Paris Jonathan reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Paris Jonathan reported acquisition or exercise transactions in this Form 4 filing.

Definitive Healthcare Corp. reported that Chief Legal Officer Jonathan Paris received a grant of 481,505 restricted stock units, each representing one share of Class A common stock. According to the award terms, 25% of these RSUs vest on March 1, 2027, with 6.25% vesting every three months over the following three years, contingent on his continued service.

Insider Trade Summary

Grant/Award: 481,505 shares

Grant/Award 1 txn

Insider Paris Jonathan

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	481,505	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 902,854 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Class A Common Stock, par value $0.001, with 25% of the RSUs vesting on March 1, 2027, followed by vesting of 6.25% every three months thereafter over the subsequent three years, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Definitive Healthcare (DH) disclose for Jonathan Paris?

Definitive Healthcare disclosed that Chief Legal Officer Jonathan Paris received 481,505 restricted stock units. Each RSU represents one share of Class A common stock, structured as an equity award rather than a cash purchase or sale in the open market.

How many shares are covered by Jonathan Paris’s RSU grant at Definitive Healthcare (DH)?

The grant to Jonathan Paris covers 481,505 restricted stock units at Definitive Healthcare. Each RSU corresponds to one share of Class A common stock, giving him a significant potential future equity interest subject to vesting and continued service conditions.

What is the vesting schedule for the RSUs granted to Jonathan Paris at DH?

The RSUs granted to Jonathan Paris vest over four years. Twenty-five percent vest on March 1, 2027, with an additional 6.25% vesting every three months thereafter for three years, provided he continues serving at Definitive Healthcare through each vesting date.

Did Jonathan Paris buy or sell Definitive Healthcare (DH) shares in this Form 4?

This Form 4 reports an equity award, not an open-market trade. Jonathan Paris acquired 481,505 restricted stock units as a grant, with no purchase price per share, and vesting tied to his continued service at Definitive Healthcare.

What type of security was reported in Jonathan Paris’s Form 4 for Definitive Healthcare (DH)?

The filing reports restricted stock units tied to Class A common stock of Definitive Healthcare. Each RSU represents a contingent right to receive one share, subject to a multi-year vesting schedule based on Jonathan Paris’s ongoing employment with the company.

How many Definitive Healthcare (DH) shares does Jonathan Paris hold after this RSU grant?

Following the reported RSU award, Jonathan Paris is shown as beneficially owning 902,854 shares or units of Definitive Healthcare Class A common stock. This updated total reflects the newly granted 481,505 restricted stock units in his direct ownership position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 04:54 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paris Jonathan

(Last) (First) (Middle)

C/O DEFINITIVE HEALTHCARE CORP.

492 OLD CONNECTICUT PATH, SUITE 401

(Street)

FRAMINGHAM MA 01701

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Definitive Healthcare Corp. [ DH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/24/2026		A		481,505(1)	A	$0	902,854	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Class A Common Stock, par value $0.001, with 25% of the RSUs vesting on March 1, 2027, followed by vesting of 6.25% every three months thereafter over the subsequent three years, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

	/s/ Jonathan Paris	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.